61
Participants
Start Date
November 30, 2008
Primary Completion Date
August 31, 2013
Study Completion Date
September 30, 2013
bendamustine
120 mg/m2 IV, Days 1, 2 of Cycles 1-6
rituximab
375 mg/m2 IV, Day 1 of Cycles 1-6
Pharmatech Oncology Study Site, The Bronx
Pharmatech Oncology Study Site, Bay Shore
Pharmatech Oncology Study Site, East Setauket
Pharmatech Oncology Study Site, Gettysburg
Pharmatech Oncology Study Site, Bethlehem
Pharmatech Oncology Study Site, Washington D.C.
Pharmatech Oncology Study Site, Washington D.C.
Pharmatech Oncology Study Site, Hilton Head
Pharmatech Oncology Study Site, Gainesville
Pharmatech Oncology Study Site, Titusville
Pharmatech Oncology Study Site, Boynton Beach
Pharmatech Oncology Study Site, Brooksville
Pharmatech Oncology Study Site, Germantown
Pharmatech Oncology Study Site, Jackson
Pharmatech Oncology Study Site, Paducah
Pharmatech Oncology Study Site, Columbus
Pharmatech Oncology Study Site, Akron
Pharmatech Oncology Study Site, Muncie
Pharmatech Oncology Study Site, Lafayette
Pharmatech Oncology Study Site, Dubuque
Pharmatech Oncology Study Site, Joliet
Pharmatech Oncology Study Site, Chesterfield
Pharmatech Oncology Study Site, Richardson
Pharmatech Oncology Study Site, Fort Worth
Pharmatech Oncology Study Site, Corpus Christi
Pharmatech Oncology Study Site, Austin
Pharmatech Oncology Study Site, Lubbock
Pharmatech Oncology Study Site, Beverly Hills
Pharmatech Oncology Study Site, Fountain Valley
Pharmatech Oncology Study Site, Oxnard
Pharmatech Oncology Study Site, York Village
Pharmatech Oncology Study Site, Cherry Hill
Pharmatech Oncology Study Site, Phillipsburg
Lead Sponsor
Collaborators (1)
Cephalon
INDUSTRY
Pharmatech
INDUSTRY